QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)

Seagen Stock Price, News & Analysis (NASDAQ:SGEN)

$215.83
+2.70 (+1.27%)
(As of 12/5/2023 ET)
Compare
Today's Range
$212.67
▼
$215.95
50-Day Range
$211.74
▼
$217.45
52-Week Range
$116.08
▼
$217.51
Volume
1.42 million shs
Average Volume
1.35 million shs
Market Capitalization
$40.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$193.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Seagen MarketRank™ Stock Analysis

Analyst Rating
Hold
2.35 Rating Score
Upside/​Downside
10.6% Downside
$193.00 Price Target
Short Interest
Bearish
5.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.55
Upright™ Environmental Score
News Sentiment
0.82mentions of Seagen in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$5.98 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.86) to ($1.86) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.68 out of 5 stars

Medical Sector

815th out of 949 stocks

Biological Products, Except Diagnostic Industry

130th out of 149 stocks

See Top Rated MarketRank™ Stocks Here

SGEN stock logo

About Seagen Stock (NASDAQ:SGEN)

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

SGEN Stock Price History

SGEN Stock News Headlines

December 5, 2023 | msn.com
Seagen gains amid options trades, optimism for FTC approval for Pfizer deal
December 3, 2023 | benzinga.com
Seagen Stock (NASDAQ:SGEN), Guidance and Forecast
December 5, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
December 2, 2023 | americanbankingnews.com
Seagen Inc. (NASDAQ:SGEN) Given Consensus Recommendation of "Hold" by Analysts
December 1, 2023 | finance.yahoo.com
Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?
December 1, 2023 | finance.yahoo.com
Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag
November 30, 2023 | businesswire.com
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV ® (enfortumab vedotin-ejfv) with KEYTRUDA ® (pembrolizumab) for First-Line ...
November 30, 2023 | msn.com
FDA to decide on approving Keytruda/Padcev combo therapy by May 9
December 5, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
November 28, 2023 | msn.com
Pfizer CFO reiterates Seagen closing expected later this year, early next year
November 28, 2023 | americanbankingnews.com
Seagen Target of Unusually Large Options Trading (NASDAQ:SGEN)
November 20, 2023 | benzinga.com
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,600 Today
November 15, 2023 | nasdaq.com
Validea Detailed Fundamental Analysis - SGEN
November 14, 2023 | finance.yahoo.com
Seagen Inc CEO David Epstein Sells Over 10,000 Shares: An Insider Sell Analysis
November 10, 2023 | msn.com
Pfizer may file substantial compliance with FTC on Seagen in 3-4 weeks - CNBC
November 8, 2023 | morningstar.com
Seagen Inc Ordinary Shares
November 3, 2023 | markets.businessinsider.com
Seagen’s Stock Hold Rating: Q3 Earnings Growth, EV-302 Study, and Pending Pfizer Deal
November 3, 2023 | benzinga.com
Here's How Much You Would Have Made Owning Seagen Stock In The Last 15 Years
November 3, 2023 | finance.yahoo.com
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2, 2023 | businesswire.com
New Data for ADCETRIS ® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30 ...
November 2, 2023 | finance.yahoo.com
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate
November 1, 2023 | finance.yahoo.com
Seagen Inc (SGEN) Reports 33% Increase in 3Q23 Net Product Sales
November 1, 2023 | benzinga.com
Looking At Seagen's Recent Unusual Options Activity
November 1, 2023 | finance.yahoo.com
Seattle Genetics (SGEN) Reports Q3 Earnings: What Key Metrics Have to Say
November 1, 2023 | markets.businessinsider.com
Seagen Inc Q3 Loss increases, misses estimates
November 1, 2023 | finance.yahoo.com
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress
October 31, 2023 | benzinga.com
Earnings Outlook For Seagen
See More Headlines
Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/21/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SGEN
CUSIP
81257810
CIK
1060736
Web
www.seattlegenetics.com
Phone
(425) 527-4000
Fax
425-527-4001
Employees
3,256
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$193.00
High Stock Price Target
$229.00
Low Stock Price Target
$129.00
Potential Upside/Downside
-10.2%
Consensus Rating
Hold
Rating Score (0-4)
2.35
Research Coverage
17 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-610,310,000.00
Net Margins
-32.61%
Pretax Margin
-32.12%
Return on Equity
-28.06%
Return on Assets
-20.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.67
Quick Ratio
2.12

Sales & Book Value

Annual Sales
$1.96 billion
Price / Sales
20.57
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$15.10 per share
Price / Book
14.24

Miscellaneous

Outstanding Shares
187,700,000
Free Float
139,084,000
Market Cap
$40.36 billion
Optionable
Optionable
Beta
0.32

Social Links

Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Should I Buy Seagen Stock? SGEN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Seagen was last updated on Tuesday, November 28, 2023 at 9:40 AM.

Pros

Here are some ways that investors could benefit from investing in Seagen Inc.:

  • Seagen Inc. is a biotechnology company that develops and commercializes therapies for the treatment of cancer. With the increasing prevalence of cancer worldwide, there is a growing demand for innovative and effective cancer treatments.
  • Seagen's ADCETRIS is an antibody-drug conjugate (ADC) that has shown promising results in the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. This product has the potential to address a significant unmet medical need in these patient populations.
  • TUKYSA, an oral small molecule tyrosine kinase inhibitor developed by Seagen, has been approved for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. This product offers a targeted therapy option for a specific subset of breast cancer patients.
  • Seagen has a strong pipeline of potential new therapies in various stages of development. This indicates the company's commitment to innovation and its potential for future growth.
  • The recent insider activity, including the purchase of Seagen's stock by institutional investors and the sale of shares by company insiders, suggests confidence in the company's prospects and may be seen as a positive signal by investors.

Cons

Investors should be bearish about investing in Seagen Inc. for these reasons:

  • Investing in biotechnology companies carries inherent risks, including the potential for clinical trial failures, regulatory challenges, and competition from other companies in the market. These risks can impact the financial performance and stock price of Seagen Inc.
  • The stock price of Seagen Inc. may be subject to volatility, as it is influenced by various factors such as market conditions, investor sentiment, and news related to the company's products or industry.
  • While Seagen has a strong pipeline, the success of its potential new therapies is not guaranteed. The development and commercialization of new drugs involve significant time, resources, and regulatory approvals, and there is always a risk of failure or delays in the process.
  • The biotechnology industry is highly competitive, with many companies vying for market share and investment. Seagen Inc. faces competition from both established pharmaceutical companies and emerging biotech firms, which could impact its market position and financial performance.
  • Investors should carefully consider their risk tolerance and investment goals before investing in Seagen Inc. It is important to conduct thorough research and seek professional advice to make informed investment decisions.














SGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Seagen stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last twelve months. There are currently 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings or view top-rated stocks.

What is Seagen's stock price target for 2024?

17 equities research analysts have issued twelve-month target prices for Seagen's stock. Their SGEN share price targets range from $129.00 to $229.00. On average, they anticipate the company's share price to reach $193.00 in the next year. This suggests that the stock has a possible downside of 10.6%.
View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts.

How have SGEN shares performed in 2023?

Seagen's stock was trading at $128.51 at the start of the year. Since then, SGEN shares have increased by 67.9% and is now trading at $215.83.
View the best growth stocks for 2023 here.

When is Seagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our SGEN earnings forecast.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) issued its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.33. The biotechnology company had revenue of $648.65 million for the quarter, compared to the consensus estimate of $635.10 million. Seagen had a negative net margin of 32.61% and a negative trailing twelve-month return on equity of 28.06%. The company's revenue was up 27.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.03) earnings per share.

What ETFs hold Seagen's stock?

ETFs with the largest weight of Seagen (NASDAQ:SGEN) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), AltShares Event-Driven ET (EVNT), Principal Healthcare Innovators ETF (BTEC) and AltShares Merger Arbitrage ETF (ARB).

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Who are Seagen's major shareholders?

Seagen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Pentwater Capital Management LP (0.00%), Primecap Management Co. CA (3.34%), Bluefin Capital Management LLC (0.00%), Maven Securities LTD (0.00%), HAP Trading LLC (0.00%) and Barclays PLC (0.94%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David R Epstein, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends.

How do I buy shares of Seagen?

Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Seagen have any subsidiaries?
The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More
This page (NASDAQ:SGEN) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -